Advanced Therapy Chain-of-Identity Software Market to Reach USD 95.8 Million by 2034 at 22.0% CAGR as Cell and Gene Therapy Manufacturers Invest in Digital Traceability Solutions
The global advanced therapy chain-of-identity software market is experiencing substantial growth as pharmaceutical companies, biotechnology developers and treatment centres increasingly focus on maintaining accurate patient and product identification throughout advanced therapy manufacturing and delivery processes. Chain-of-identity software plays a critical role in tracking patient-specific biological materials from collection through manufacturing, quality control, release and final administration. These solutions help maintain accurate identity records, improve chain-of-custody visibility and reduce the risk of patient-material mismatches. Increasing adoption of personalized cell and gene therapies, expanding CAR-T treatment programmes and growing requirements for digital traceability are strengthening demand for specialized software platforms.


According to a report by IntelMarketResearch, the Global Advanced Therapy Chain-of-Identity Software Market was valued at USD 16.0 million in 2025 and is estimated to reach USD 19.5 million in 2026. The market is projected to reach USD 95.8 million by 2034, representing a CAGR of 22.0% during the forecast period. Growing personalized medicine adoption, increasing demand for traceable digital hand-offs and expanding advanced therapy manufacturing operations are supporting market expansion.


Read the complete Advanced Therapy Chain-of-Identity Software Market report: https://www.intelmarketresearch.com/advanced-therapy-chain-of-identity-software-market--328-66775




Contact:


IntelMarketResearch
Website: https://www.intelmarketresearch.com
Phone: +91 9169164321
Email: help@intelmarketresearch.com
Advanced Therapy Chain-of-Identity Software Market to Reach USD 95.8 Million by 2034 at 22.0% CAGR as Cell and Gene Therapy Manufacturers Invest in Digital Traceability Solutions The global advanced therapy chain-of-identity software market is experiencing substantial growth as pharmaceutical companies, biotechnology developers and treatment centres increasingly focus on maintaining accurate patient and product identification throughout advanced therapy manufacturing and delivery processes. Chain-of-identity software plays a critical role in tracking patient-specific biological materials from collection through manufacturing, quality control, release and final administration. These solutions help maintain accurate identity records, improve chain-of-custody visibility and reduce the risk of patient-material mismatches. Increasing adoption of personalized cell and gene therapies, expanding CAR-T treatment programmes and growing requirements for digital traceability are strengthening demand for specialized software platforms. According to a report by IntelMarketResearch, the Global Advanced Therapy Chain-of-Identity Software Market was valued at USD 16.0 million in 2025 and is estimated to reach USD 19.5 million in 2026. The market is projected to reach USD 95.8 million by 2034, representing a CAGR of 22.0% during the forecast period. Growing personalized medicine adoption, increasing demand for traceable digital hand-offs and expanding advanced therapy manufacturing operations are supporting market expansion. Read the complete Advanced Therapy Chain-of-Identity Software Market report: https://www.intelmarketresearch.com/advanced-therapy-chain-of-identity-software-market--328-66775 Contact: IntelMarketResearch Website: https://www.intelmarketresearch.com Phone: +91 9169164321 Email: help@intelmarketresearch.com
Advanced Therapy Chain-of-Identity Software Market Forecast
Global Advanced Therapy Chain-of-Identity Software market was valued at USD 16.0 million in 2025 and projected to reach USD 95.8 million by 2034 at 22.0% CAGR.
0 Комментарии 0 Поделились 0 Отзывы
Реклама
VintFint https://vintfint.com